DUBLIN - It's not over until it's over. Celgene Corp.'s fabled business development engine is still cranking out deals, even though its acquisition by Bristol-Myers Squibb Co. now looks likely to close this year, following this week's $13.4 billion divestment of Otezla (apremilast) to Amgen Inc.